You might also like
Minimal residual disease in acute myeloid leukemia: perspectives in the clinical, technical, and guideline domains – a report
FLT3 testing methods
Explanation of the practicalities of FLT3 testing and the difference between testing methods.
Find out more
Advancing insights into evolution of FLT3 mutations in AML. Explore the CLEVO study³.
This prospective, non-interventional study demonstrated that patients with AML1 undergo substantial clonal evolution over their disease course and are not tested in a timely manner. In this study, more than 10% of patients gained or lost FLT32 mutations at first occurrence of relapsed/refractory (R/R) AML.
Intended for: practitioners hematology
Why: uup-to-date knowledge about FLT3 mutations
When: read now
1: Acute Myeloid Leukemia 2: FMS-like Tyrosine Kinase 3. 3: Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A non-interventional cohort study (CLEVO)
MAT-BE-NON-2026-00056 MAY 2026